Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (“NEAT”) receptor, and related compositions and methods.

Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods.

Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods.

Abstract: The present invention relates to agonists, antagonists, and other molecules that specifically bind SIGLEC-6 on mast cells, their use in the treatment of asthma and other SIGLEC-6 mediated diseases or disorders, methods of diagnosing such diseases or disorders, and methods of screening for candidate compounds capable of modulating SIGLEC-6 activity in mast cells. The present invention also relates to the diagnosis and treatment of B-cell related disorders using compounds that bind and/or modulate SIGLEC-6.

Abstract: Novel nuclear factor of activated T cells (“NFAT”) activating receptor useful for producing agonist and antagonist antibodies that regulate the cellular production and expression of cytokines and cellular receptors. The receptor is a 270 amino acid type I transmembrane protein with a calculated molecular mass of about 30 kD. The receptor has a putative signal peptide at the N-terminal (amino acids 1-42), an Ig-domain (amino acids 43-150) in the extracellular region, a predicted transmembrane domain (amino acids 164-186), and an predicted ITAM motif (amino acids 220-235) in the cytoplasmic region. The receptor activates NFAT, IL-13 and TNF alpha promoter reporter activities.